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A child presenting with ataxia may pose a diagnostic 
dilemma. After excluding the common causes, 
including toxins, infection and tumours, one needs 
to look carefully for a possible genetic cause. With 
limited genetic testing available in South Africa (SA), 
a definitive answer is not always found.
It is estimated that there are 360 000 HIV-positive children 
under 15 years of age in SA,[1] 44% of whom are on antiretroviral 
therapy (ART).[2] These young patients often pose unique diagnostic 
challenges. We highlight an important differential to consider in 
HIV-positive paediatric patients presenting with ataxia.
Case reports
Case 1
A 6-year-old girl presented with an acute onset of confusion, 
vomiting and difficulty in walking. She was HIV-positive and had 
been on ART for the past year. She was on the standard first-line 
regimen comprising abacavir, lamivudine and efavirenz (EFV), each 
of which was dosed appropriately according to her weight and the 
Southern African HIV Clinicians Society guidelines. Her viral load 
a month before admission had been <100 RNA copies/mL and her 
CD4 count was 250 cells/µL. There was no history of toxin ingestion.
On examination she was markedly ataxic and unable to walk or sit 
unsupported. She was also noted to have titubation, dysmetria and 
dysdiadochokinesia.
Investigations for a possible infectious cause were undertaken. 
The findings on lumbar puncture (LP) were normal and serological 
investigations for varicella virus were negative. However, a computed 
tomography brain scan was suggestive of possible inflammation of 
the cerebellum (‘cerebellitis’). Magnetic resonance imaging (MRI) of 
the brain, to better delineate the posterior fossa structures, revealed 
a normal brain.
While the signs of cerebellar dysfunction had started acutely, their 
continuation for more than 2 weeks prompted further investigation 
for an inherited cause of progressive chronic ataxia (our differential 
diagnosis included ataxia telangiectasia (no telangiectasia were 
present clinically and the immunoglobulin levels were normal), 
abetalipoproteinaemia, Friedreich’s ataxia and spinocerebellar ataxia. 
Genetic testing was negative.
The vomiting, with the persistent ataxia, led to consideration 
of possible medication toxicity. The EFV level was 69 110 ng/mL 
(v. reference 1 000 ng/mL as the minimum target trough concen-
tration). On stopping the EFV, the patient showed signs of clinical 
improvement with resolution of vomiting and ataxia. A protease 
inhibitor was not started at this time as the elevated EFV levels were 
expected to act as the third antiretroviral agent.
A repeat EFV level done 7 days after stopping the drug showed 
persistently high levels (49 000 ng/mL), but the patient was able 
to walk unsupported and the dysmetria and dysdidadokinesia had 
improved. The decision was made to change the patient to lopinavir/
ritonavir, and a month after stopping the EFV she showed no residual 
cerebellar signs.
Case 2
A 13-year-old girl was referred to the paediatric neurology clinic 
at Chris Hani Baragwanath Academic Hopsital, Johannesburg, 
SA, with an acute onset of ataxic gait. She had been diagnosed 
with HIV infection 3 years previously and staged as World Health 
Organization clinical stage IV, but was only started on ART (abacavir, 
lamivudine and EFV) 18 months before her referral. The doses were 
all appropriate for weight accor ding to the Southern African HIV 
Clinicians Society guidelines. She was virally suppressed, with an 
HIV viral load of 28 RNA copies/mL and a CD4 count of 554 cells/µL.
On examination she had a broad-based ataxic gait. Other cerebellar 
signs included dysmetria, dysdiadochokinesia and mild staccato 
speech, but no nystagmus.
Initial investigations were done to look for a possible infective 
cause. The findings on LP were normal, and serological investigations 
for varicella were negative. An MRI scan of the brain showed no 
intracranial lesions, structural changes or features of infection.
Before investigating further, and on the basis of experience in case 1, 
we looked for possible EFV toxicity. The level was 16 274 ng/mL.
Three weeks after stopping the drug, and relying on the elevated 
EFV levels to continue to act as the third antiretroviral agent, the EFV 
level had dropped to 1 002 ng/mL with clinical improvement in the 
patient’s gait and resolution of her dysmetria. It was decided to opt 
for lopinavir/ritonavir as her third antiretroviral agent, and EFV was 
discontinued.
EFV drug level methodology
EFV is administered as a once-daily dose given at night to limit 
side-effects, and blood samples for measurement of steady-state drug 
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levels were collected from our patients during the day before 12h00. 
Samples were collected in a 5 mL heparinised BD Vacutainer vial 
(BD Plymouth PL6 7BP, UK) and stored at 2 - 8oC until analysed. 
Analysis was performed using liquid chromatography-tandem mass 
spectrometry (LC-MS MS) at Ampath Laboratory in Johannesburg. 
An LC-MS MS TQD (triple quad detector) instrument from Waters 
in electrospray positive ionisation mode was used, employing an 
external standard from ChromSystems (6PLUS1 Multilevel Plasma 
Calibrator Set Anti-HIV Drugs) for quantification. EFV is identified 
according to its molecular mass of parent ion 316 as well as one 
daughter ion of molecular mass 244 and retention time.
Discussion
Acute ataxia is defined as unsteadiness of walking or of fine motor 
movement with a duration of <72 hours. The most common causes 
are post-infectious acute cerebellar ataxia, toxin ingestion and 
Guillain-Barré syndrome.[3] However, the possibility of a mass lesion 
must always be excluded.
The reported prevalence of neurological abnormalities in HIV-
positive children ranges from 10% to 68%.[4] An SA study found 
the prevalence of neurological complications to be 59%, the most 
common being HIV encephalopathy and long-tract motor signs; 
however, no cases of cerebellar dysfunction were documented in that 
study.[4] The occurrence of ataxia in an HIV-positive individual is 
rare, with the chronic sequelae being neurocognitive impairment and 
polyneuropathy.[5]
Ataxia in the setting of HIV is generally secondary to an 
infectious, vascular or neoplastic cerebellar lesion. Most infections 
are opportunistic and unlikely to occur in the setting of a sufficient 
CD4 count.[5] Vascular or mass lesions are readily excluded with 
neuroimaging.
EFV is a non-nucleoside reverse transcriptase inhibitor that 
dis rupts HIV replication by inhibiting the reverse transcriptase 
enzyme. EFV is known to have good central nervous system (CNS) 
penetration,[6] and owing to its long half-life is administered as a 
once-daily dose. EFV forms part of the SA first-line ART regimen for 
children >3 years of age and >10 kg in weight.[7]
CNS symptoms are the most frequently reported side-effects in HIV-
positive patients on EFV, and include dizziness, headache, confusion, 
stupor, impaired concentration, agitation, amnesia, depersonalisation, 
hallucinations, insomnia and strange dreams.[6,8-14] The frequency of 
CNS side-effects is estimated to be 20 - 40%.[10] The majority of patients 
who develop CNS and psychiatric adverse effects do so in the first 6 
weeks of treatment,[11] with most symptoms resolving by 6 - 10 weeks 
after treatment initiation.[6] One article documented neurocerebellar 
side-effects – self-reported dizziness, ataxia, insomnia, bad dreams and 
hallucinations, without objective assessment of ataxia – in patients using 
EFV, occurring most frequently in the first month after initiating EFV 
and declining with time.[12]
Many studies have looked at the effect of the EFV drug level on the 
frequency of side-effects. Marzolini et al.[10] reported a 24% increase 
in CNS side-effects if the plasma level was >4 000 ng/mL. However, 
other researchers have found no correlation between adverse effects 
and plasma concentrations.[8,9] Gutierrez et al.[13] nevertheless found 
that CNS side-effects associated with long-term EFV administration 
were related to plasma levels.
Wide variations in the plasma levels of patients on the same 
weight-appropriate dose of EFV have been demonstrated. One factor 
attributing to this individual variation in levels is polymorphism of 
the CYP2B6 enzyme on cytochrome P450, as EFV is a substrate of 
this enzyme.[9] The prevalence of the slow-metabolising genotype 
was 30% in a Botswana study, and other studies have also shown a 
relatively higher incidence of this genotype in African populations.[14]
Conclusion
Ataxia in both our patients was attributable to the high plasma 
concentration of EFV, which was at least four times greater than 
the toxic level (4 000 ng/mL) described by Marzolini et al.[10] and 
improved when the drug was discontinued. Polymorphism of the 
CYP2B6 enzyme may explain the very high plasma levels seen.
When a child known to be on EFV presents with acute progressive 
ataxia, after excluding the common causes, the EFV plasma levels 
should be checked; if they are toxic, stopping the agent and substituting 
it with an alternative class of antiretroviral drug should be considered.
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